1. Home
  2. HURA vs AKA Comparison

HURA vs AKA Comparison

Compare HURA & AKA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • HURA
  • AKA
  • Stock Information
  • Founded
  • HURA 2009
  • AKA 2018
  • Country
  • HURA United States
  • AKA United States
  • Employees
  • HURA N/A
  • AKA N/A
  • Industry
  • HURA
  • AKA Catalog/Specialty Distribution
  • Sector
  • HURA
  • AKA Consumer Discretionary
  • Exchange
  • HURA Nasdaq
  • AKA Nasdaq
  • Market Cap
  • HURA 103.3M
  • AKA 110.4M
  • IPO Year
  • HURA N/A
  • AKA 2021
  • Fundamental
  • Price
  • HURA $2.33
  • AKA $11.28
  • Analyst Decision
  • HURA Strong Buy
  • AKA Buy
  • Analyst Count
  • HURA 2
  • AKA 4
  • Target Price
  • HURA $11.50
  • AKA $22.50
  • AVG Volume (30 Days)
  • HURA 475.4K
  • AKA 7.6K
  • Earning Date
  • HURA 08-15-2025
  • AKA 08-06-2025
  • Dividend Yield
  • HURA N/A
  • AKA N/A
  • EPS Growth
  • HURA N/A
  • AKA N/A
  • EPS
  • HURA N/A
  • AKA N/A
  • Revenue
  • HURA N/A
  • AKA $586,514,000.00
  • Revenue This Year
  • HURA N/A
  • AKA $6.60
  • Revenue Next Year
  • HURA $69.15
  • AKA $4.14
  • P/E Ratio
  • HURA N/A
  • AKA N/A
  • Revenue Growth
  • HURA N/A
  • AKA 8.09
  • 52 Week Low
  • HURA $1.80
  • AKA $7.00
  • 52 Week High
  • HURA $10.49
  • AKA $32.25
  • Technical
  • Relative Strength Index (RSI)
  • HURA N/A
  • AKA 48.54
  • Support Level
  • HURA N/A
  • AKA $10.75
  • Resistance Level
  • HURA N/A
  • AKA $11.59
  • Average True Range (ATR)
  • HURA 0.00
  • AKA 0.62
  • MACD
  • HURA 0.00
  • AKA 0.00
  • Stochastic Oscillator
  • HURA 0.00
  • AKA 47.91

About HURA TuHURA Biosciences Inc. Common Stock

TuHURA Biosciences Inc is a Phase 3 registration stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. The company's personalized cancer vaccine candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. It is preparing to initiate a single randomized placebo-controlled Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda (pembrolizumab) in first-line treatment for advanced or metastatic Merkel Cell Carcinoma.

About AKA a.k.a. Brands Holding Corp.

a.k.a. Brands Holding Corp is an online fashion retailer focused on acquiring and accelerating the growth of next-generation, digitally native fashion brands targeting Gen Z and Millennial customers. The brands of the company are two women's brands, Princess Polly and Petal & Pup, and two streetwear brands, Culture Kings and mnml. The company derives maximum revenue from Australia/New Zealand.

Share on Social Networks: